Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AM Rx vs EmbraceRX

AM Rx
Graded #491

Lower grade

vs+9
EmbraceRX
Graded #362

Higher grade

The verdict

EmbraceRX takes it — 58.6/100 to 49.6/100.

EmbraceRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. EmbraceRX (Embrace Rx) is a clinician-guided telehealth platform offering pharmacy-compounded medications prescribed online, partnered with the Samaritan MD physician network.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAM Rx +5
50
45
Dose & formulationAM Rx +9
65
56
Clinical oversightEmbraceRX +35
41
76
Labs & monitoringEmbraceRX +3
49
52
FulfillmentEmbraceRX +15
58
73
Contract termsEmbraceRX +35
20
55
AM Rx · left barEmbraceRX · right bar

The numbers

MetricAM RxEmbraceRX
WeighScore49.6/10058.6/100
GradeCC
Scorecard rank#491#362
Semaglutide$151/mo (quarterly plan, plus a separate fee, compounded)Not disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
AM Rx

Graded #491 · C

Strengths

  • Insurance coordination for brand-name GLP-1s — as low as $25/mo
  • All four major brand-name GLP-1s available (Ozempic, Wegovy, Zepbound, Mounjaro)
  • HSA and FSA accepted
  • Video visits available with providers averaging 10+ years' experience
  • Compounded semaglutide from $151/mo on the quarterly plan

Where it loses points

  • Active FTC/DOJ lawsuit over deceptive billing and subscription practices
  • Novo Nordisk false-advertising lawsuit (Aug 2025)
  • Parent company Zealthy holds a BBB D- rating with 2,370+ complaints
  • Trustpilot 2.0/5, with 85% one-star reviews citing billing disputes and unreachable support
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
EmbraceRX

Graded #362 · C

Strengths

  • Broad compounded GLP-1 menu — semaglutide (+B12), tirzepatide, oral semaglutide/tirzepatide capsules, plus Lipo-B
  • Large peptide/longevity catalog (BPC-157, GHK-Cu, NAD+, MOTS-C) across injectable, oral, topical, and nasal formats
  • Clinician-guided, compounded at FDA-registered pharmacies; partners with a licensed physician network (Samaritan MD)
  • Full legal suite published (Terms, Privacy, HIPAA Notice, CCPA, Returns & Refunds)

Where it loses points

  • Pricing not shown upfront — revealed only at checkout after a dose selection
  • Offers investigational/research compounds (e.g., retatrutide, AOD-9604) that are not FDA-approved
  • Compounding pharmacy partner not named ('FDA-registered pharmacies')
  • Not LegitScript-certified (no certification displayed)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard